175 related articles for article (PubMed ID: 11018188)
1. Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes.
Januzzi JL; Hahn SS; Chae CU; Giugliano R; Lewandrowski K; Theroux P; Jang IK
Am J Cardiol; 2000 Oct; 86(7):713-7. PubMed ID: 11018188
[TBL] [Abstract][Full Text] [Related]
2. Elevation in serum troponin I predicts the benefit of tirofiban.
Januzzi JL; Chae CU; Sabatine MS; Jang IK
J Thromb Thrombolysis; 2001 May; 11(3):211-5. PubMed ID: 11577259
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
[TBL] [Abstract][Full Text] [Related]
4. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
Zhao XQ; Théroux P; Snapinn SM; Sax FL
Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731
[TBL] [Abstract][Full Text] [Related]
5. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Alexander JH; Harrington RA
Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
[TBL] [Abstract][Full Text] [Related]
6. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Huynh T; Theroux P; Snapinn S; Wan Y;
Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD
Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535
[TBL] [Abstract][Full Text] [Related]
8. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Okmen E; Cakmak M; Tartan Z; Cam N
Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
[TBL] [Abstract][Full Text] [Related]
9. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104
[TBL] [Abstract][Full Text] [Related]
10. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management.
Heeschen C; Hamm CW; Goldmann B; Deu A; Langenbrink L; White HD
Lancet; 1999 Nov; 354(9192):1757-62. PubMed ID: 10577636
[TBL] [Abstract][Full Text] [Related]
11. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
12. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
Servoss SJ; Wan Y; Snapinn SM; DiBattiste PM; Zhao XQ; Theroux P; Jang IK; Januzzi JL;
Am J Cardiol; 2004 Apr; 93(7):843-7. PubMed ID: 15050486
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.
Théroux P; Alexander J; Pharand C; Barr E; Snapinn S; Ghannam AF; Sax FL
Circulation; 2000 Nov; 102(20):2466-72. PubMed ID: 11076818
[TBL] [Abstract][Full Text] [Related]
14. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
Morrow DA; Antman EM; Snapinn SM; McCabe CH; Theroux P; Braunwald E
Eur Heart J; 2002 Feb; 23(3):223-9. PubMed ID: 11792137
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
[TBL] [Abstract][Full Text] [Related]
16. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
Harrington RA
Am Heart J; 1999 Oct; 138(4 Pt 2):276-86. PubMed ID: 10502233
[TBL] [Abstract][Full Text] [Related]
17. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.
Kim JH; Jeong MH; Rhew JY; Lim JH; Yun KH; Kim KH; Kang DK; Hong SN; Lim SY; Lee SH; Lee YS; Hong YJ; Park HW; Kim W; Ahn YK; Moon Y; Cho JG; Park JC; Kang JC
Circ J; 2005 Feb; 69(2):159-64. PubMed ID: 15671606
[TBL] [Abstract][Full Text] [Related]
19. [Risk stratification in acute coronary syndrome].
Goldmann BU; Hamm CW
Herz; 2001 Apr; 26 Suppl 1():24-9. PubMed ID: 11349623
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of low-molecular-weight heparin in acute coronary syndromes.
Wallentin L
Am Heart J; 2000 Feb; 139(2 Pt 2):S29-32. PubMed ID: 10650313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
